News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Phenomix Corporation Announces PHX1149 Phase 2b Clinical Trial Results for Type 2 Diabetes
May 19, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SAN DIEGO--(BUSINESS WIRE)--Phenomix Corporation announced today that PHX1149, a dipeptidyl peptidase-4 (DPP-4) inhibitor, demonstrated positive results in a Phase 2b clinical trial for the treatment of Type 2 diabetes.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Phenomix Corporation
MORE ON THIS TOPIC
Deals
Stoffels strikes up new biotech in return to Galapagos cell therapy mission
October 15, 2026
·
4 min read
·
Annalee Armstrong
Neuroscience
Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop
October 15, 2026
·
3 min read
·
Tristan Manalac
Neuropsychiatric disorders
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
October 15, 2026
·
3 min read
·
Tristan Manalac
IN PARTNERSHIP WITH CYTIVA
The decisions behind scientific progress
October 15, 2026
·
1 min read
·
Jennifer C. Smith-Parker
